A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

• •Participants who are 16 to 17 years old would be enrolled after consultation with the Medical Monitor
• •Histologically or cytologically documented, incurable or metastatic solid tumor or hematologic malignancy that is advanced (non-resectable) or recurrent and progressing since the last anti-tumor therapy and for which no recognized standard curative therapy exists
• •Representative tumor specimens in paraffin blocks (preferred) or at least 15 unstained slides, with an associated pathology report
• •Adequate hematologic and end organ function
• •Measurable disease per RECIST v1.1 for participants with solid malignancies. Disease-specific criteria for participants with prostate cancer, glioblastoma multiforme (GBM), malignant lymphoma, or multiple myeloma
• •For women of childbearing potential: agreement to remain abstinent or use contraceptive methods
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •For participants who will undergo serial biopsy in dose-escalation cohort, baseline tumor tissue samples should be of core needle biopsies for deep tumor tissue or organs or excisional or punch biopsies for cutaneous or subcutaneous lesions (\>/=5 millimeter \[mm\] in diameter amenable to serial biopsy)